M&T Bank
CORT icon

M&T Bank’s Corcept Therapeutics CORT Stock Holding History

M&T Bank’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$831K Buy
9,560
+1,101
+13% +$66.5K ﹤0.01% 980
2026
Q1 		$341K Sell
8,459
-3,297
-28% -$123K ﹤0.01% 1307
2025
Q4 		$409K Buy
11,756
+5,662
+93% +$445K ﹤0.01% 1230
2025
Q3 		$507K Buy
6,094
+495
+9% +$35.8K ﹤0.01% 983
2025
Q2 		$411K Sell
5,599
-40
-0.7% -$2.9K ﹤0.01% 1146
2025
Q1 		$644K Sell
5,639
-3,530
-38% -$215K ﹤0.01% 972
2024
Q4 		$462K Sell
9,169
-1,249
-12% -$65.4K ﹤0.01% 1208
2024
Q3 		$483K Sell
10,418
-534
-5% -$19K ﹤0.01% 1169
2024
Q2 		$356K Sell
10,952
-618
-5% -$16.9K ﹤0.01% 1238
2024
Q1 		$291K Buy
+11,570
New +$273K ﹤0.01% 1342
2018
Q4 		– Sell
-16,077
Closed -$226K – 1451
2018
Q3 		$226K Sell
16,077
-782
-5% -$10.9K ﹤0.01% 1374
2018
Q2 		$265K Buy
+16,859
New +$293K ﹤0.01% 1279

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

M&T Bank's CORT Position: Q2 2026 in Review

M&T Bank increased its Corcept Therapeutics (CORT) stake by 13% in Q2 2026, buying an estimated $66.5K and bringing the position to 9,560 shares worth $831K. The position accounts for ﹤0.01% of the portfolio, ranked #980.

M&T Bank first reported a position in CORT in Q2 2018 and has held it in 12 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • M&T Bank held 9,560 shares of Corcept Therapeutics worth $831K as of Q2 2026.
  • M&T Bank bought 1,101 Corcept Therapeutics shares in Q2 2026, an estimated $66.5K.
  • Corcept Therapeutics made up ﹤0.01% of M&T Bank's portfolio in Q2 2026, its #980 holding.
  • M&T Bank first reported a position in Corcept Therapeutics in Q2 2018 and has held it in 12 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.